In response to hand sanitizer shortages, the Gordon Center radiopharmacy lab converted itsel into a sanitizer production facility.
Gordon Center Assistant Professor Pedro Brugarolas collaborated with TED-Ed to explain the science behind how doctors use radioactive drugs and PET scans to detect and diagnose diseases like Alzheimer’s and cancer.
Fifty years after the installation of the first cyclotron at MGH, the Gordon Center perpetuates the PET imaging research tradition of the hospital with the support of two generations of researchers including some of the earliest pioneers who are still working at our center.
Radiopharmaceutical company Trace-Ability, Inc. announced that the FDA has approved the first use of its solution, Tracer-QC, for release testing Ammonia N-13 Injection at the MGH Gordon Center PET Core. Tracer-QC automates the positron emission tomography (PET) tracer release testing process, which the company says is known for its complexity. “Despite the clear value of […]
We are pleased to announce that three Research Fellows in the Gordon Center have been promoted to the title of Instructor. Congratulations to Kai Bao, Fangxu Xing, and Gengyang Yuan!
Cerveau Technologies Inc. signed an agreement with the MGH Gordon Center to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
A warm thank you to everyone who joined us for our winter holiday party. [slideshow_deploy id=’10814′]
The 12th Human Amyloid Imaging Conference will take place in Miami, Florida on January 17-19, 2018.
Dr. Keith Johnson is organizing the event with the help of co-organizers Dr. Bill Klunk (University of Pittsburgh), Dr. Chet Mathis (University of Pittsburgh) and Dr. Bill Jagust (University of California, Berkeley).
The conference includes podium and poster presentations on cutting edge research into biomarkers for Alzheimer’s-related disease.